Concomitant use of ZEPOSIA with any of these therapies would be expected to increase the risk of immunosuppression. When switching to ZEPOSIA from immunosuppressive medications, consider the ...

Most medicines for treating MS require an injection; however, oral medicines, like Zeposia, provide an easier treatment option. Zeposia is part of a newer class of medicines called sphingosine ...

Zeposia (ozanimod) is a prescription drug that’s used to treat multiple sclerosis and ulcerative colitis. Zeposia can cause side effects that range from mild to serious. Examples include upper ...

Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease. A preliminary analysis ...

Bristol Myers Squibb’s Zeposia is no longer the only S1P receptor modulator on the market for ulcerative colitis, thanks to an FDA approval for what appears to be a more effective drug from Pfizer.

Zeposia (ozanimod) is not safe to take while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can take the drug during this time. If you may ...

These findings showed that patients receiving continuous Zeposia treatment for up to five years experienced low and stable rates of whole brain volume (WBV) loss through Month 60 (annualized least ...

Final results from the DAYBREAK long-term extension study showed brain volume loss decreased during Phase 3 studies and was sustained with continuous Zeposia treatment for up to 5 years More than ...

Results add to the growing body of evidence and reinforce the safety and efficacy profile of Zeposia in relapsing forms of multiple sclerosis PRINCETON, N.J.--(BUSINESS WIRE) -- Bristol Myers Squibb ...

(2024-03-28 | NYSE:BMY) Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease ...

Patients receiving continuous Zeposia treatment for up to five years experienced low and stable rates of whole-brain volume loss. Findings from a separate safety analysis demonstrated declining or ...